We are studying whether switching from anti-C5 antibody therapy to iptacopan can help people with aHUS avoid complications. The trial will also assess the safety and effects on blood and kidney health.
Health conditions and diseases that the clinical trial is designed to study and treat.
Atypical Hemolytic Uremic Syndrome (aHUS) is a rare, serious condition that leads to the destruction of red blood cells, low platelet counts, and kidney failure. It can cause severe complications if not treated promptly.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
